帕金森病治疗市场，[药物型（多巴胺受体激动剂，Carbidopa / Levodopa，Mao-抑制剂，其他）;通过分销渠道（医院药房，在线药房，零售药房）;通过最终使用（医院，诊所）];和地理 - 趋势，分析和预测直到2025年

Report Summary

The Global Parkinson’s Disease Treatment Market to notice positive growth owing to its rising prevalence, and increasing awareness about the diagnosis of Parkinson’s disease at an initial stage.

帕金森病(PD)是一种神经退行性disorder, that is caused due to the loss of dopamine production in the brain. It leads to progressive deterioration of motor function in the human body affecting the brain, and nerve cells. It can be recognized with the barely noticeable tremor in one hand, but is one of the most significant symptoms that can help the doctors in recognizing Parkinson’s disease at an early stage. Parkinson’s disease is noticeably caused due to various environmental factors, and genetic mutations. In addition, it causes problems such as thinking difficulties, depression, and emotional change, swallowing problems, sleep disorder, constipation, and bladder problems.

Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s. The number of people globally suffering from Parkinson’s disease is around 10 million, or it ranges around 41 people per 1,00,000. Men are likely to get affected 1.5 times higher than a woman.

Parkinson’s disease, can be recognized initially through decreased movement of arms while walking, stiffness, slowness in performing any task. Moreover, some secondary symptoms include anxiety, depression, and dementia. This disease is found in the individuals with age range of around 60 years, and impairment of the disease varies from person to person. The study shows that the time that primary symptoms are observed about 60 to 80% of dopamine-producing cells are damaged in the brain. This damage to the brain cell is caused due to neurons break down, leading to loss of brain activity, and some signs of Parkinson’s disease.

Consistently increasing elder population, increased funding for research and development, and favourable government policies will support the growth of global Parkinson’s disease treatment market.

由于全球预期寿命增加，市场主要推动帕金森病的普遍存率。例如，2015年谁提出的数据表示，一个人的平均预期寿命为70年，并将继续增加。此外，领先球员的投资持续飙升，用于发现PD的各种治疗方案。地理上，日本具有最高的预期寿命，使其成为有效的位置。因此，主导公司的重点现在已经转向发展中国家。

虽然，越来越多的临床试验，用于了解帕金森疾病的病理生理学，以及发展经济体政府对医疗保健以及有效治疗的未满足需求对医疗保健的影响以及有效治疗的疾病的临床生理和投资。betway体育亚洲版入口

Moreover, key trends that have included increasing drug pipeline, rising number of the scope of gene therapy and rising number of people suffering from Parkinson’s diseases the growth of this market.

Global Parkinson’s Disease Treatment Market Taxonomy

The global market is segmented on the basis of drug type, distribution channel, end use and geography

On the basis of drug type, the market is segmented into:

• 多巴胺受体激动剂
• Carbidopa / Levodopa.
• MAO-Inhibitors
• 其他

在分销渠道的基础上，市场分段为：

• 医院Pharmacies
• 在线药店
• Retail Pharmacies

在最终使用类型的基础上，市场分段为：

• 医院
• 诊所

地理上，全球帕金森病治疗市场分为北美，欧洲，亚太地区，拉丁美洲和中东和非洲。

对帕金森病的认识升高，增加了老年人的人口和不断的政府努力，以支持基因治疗，以引领欧洲的这个市场的增长。

欧洲地区预计将在预测期间占据全球帕金森病治理市场。欧洲通过增加研发投资，拥有持续的技术发展的主要股份。

While, North America is considered to hold the second largest market share among regions, but Asia Pacific is expected to grow rapidly during the forecast period. Growing patient count along with support from governments in terms of expenditure for developing healthcare infrastructure are the major factors that anticipate to govern the growth of Parkinson’s disease treatment in Asia Pacific region during upcoming years.

Key players in the global Parkinson’s disease treatment market are:

• Teva Pharmaceuticals Inc.
• 诺华AG
• GlaxoSmithKline Inc.
• AbbVie Inc.
• Merck & Company
• Boehringer Ingelheium Inc.
• 幻销实验室
• Sun Pharma
• Valeant Pharmaceuticals
• UCB Inc.